Regorafenib (Stivarga®) for mCRC

Assessment Status Assessment Process Complete
Drug Regorafenib
Brand Stivarga®
Indication For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.
Assessment Process
Rapid review commissioned 12/09/2013
Rapid review completed 02/10/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 14/02/2014
NCPE assessment completed 30/06/2014
NCPE assessment outcome Reimbursement not Recommended

The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.

Technical Summary

Following discussions between the HSE and the company, regorafenib is now reimbursed under a patient access scheme.